Australian report questions benefits of patent term harmonisation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Australian report questions benefits of patent term harmonisation

A new report from the Australian government says that TRIPs and FTA-mandated patent term extensions may not benefit the country

The government’s Pharmaceutical Patents Review Panel released its draft report yesterday and is seeking public comments. The report evaluates “whether the system for pharmaceutical patents is effectively balancing the objectives of securing timely access to competitively priced pharmaceuticals, fostering innovation and supporting employment in research and industry”.

The 249-page report looks at many different issues, but raises particular concerns about patent term length as well as the duration of pharmaceutical patent extensions. In particular, the report points to the increase of the protection term of 20 years for all patents as required by TRIPs, noting that this change does not necessarily yield any benefit to Australia, or even patentees for that matter. Similarly, the Panel argues that Australia agreed to provide an extension for pharmaceutical patents as part of its free trade agreement with the US “without careful regard to whether this was in our own economic interest”.

The paper suggests that Australia may in fact be hurt by these longer patent terms. Not only may the government be paying more to purchase drugs protected by lengthy patent terms, but Australian generics may be put at a disadvantage. For example, the longer terms may force Australian generic manufacturers to move production overseas, whether producing for international markets where the drug has no patent production or stockpiling in anticipation of the domestic patent’s expiration. Such restrictions, the report argues, send jobs overseas and make it harder for Australian manufacturers to gain a “first mover” advantage in the generics market.

The paper also takes the position that the lengthier patent terms do not necessarily encourage investment by innovator companies. It states that it “found it difficult to believe that the prospect of additional returns from an extension of the then 16 year standard patent life could materially influence investment decisions made many years beforehand”.

Similarly, the report argues that though the cost involved in drug development is high, the incentives needed to encourage innovation may be overstated, noting that according to one study, innovator pharmaceutical companies enjoyed more than triple the profitability of non-pharmaceutical companies between 1998 and 2009. It characterised the patent extension as an indirect subsidy for the pharmaceutical industry. The report suggests that it might be more efficient to shorten the extension length to save the government hundreds of millions of dollars in drug costs, and use some of those savings to provide direct subsidies for R&D.

The full draft report may be found here. Public comments should be made to pharmapatents@ipaustralia.gov.au until April 30. Previous submissions, including those filed by Pfizer, Novartis, and Cancer Voices Australia are also available at the panel’s website.

more from across site and SHARED ros bottom lb

More from across our site

Kelly Thompson, chair of South African firm Adams & Adams, discusses self-belief, self-doubt, and the importance of saying yes
The renowned food brands were represented by a host of lawyers, including members of the firms’ IP teams
Partners at Bird & Bird and Taylor Wessing discuss how Saudi Arabia offers unique opportunities for firms dealing in IP and tech
Attorneys explain why there are early signs that the US Supreme Court could rule in favour of ISP Cox in a copyright dispute
A swathe of UPC-related hires suggests firms are taking the forum seriously, as questions over the transitional stage begin
A win for Nintendo in China and King & Spalding hiring a prominent patent litigator were also among the top talking points
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact
Attorneys predict how Lululemon’s trade dress and design patent suit against Costco could play out
Lawyers at Linklaters analyse some of the key UPC trends so far, and look ahead to life beyond the transition period
David Rodrigues, who previously worked at an IP boutique, said he may become more involved in transactional work at his new firm
Gift this article